- 专利标题: Treatment of CRTH2-mediated diseases and conditions
-
申请号: US12232446申请日: 2008-09-17
-
公开(公告)号: US20090018138A1公开(公告)日: 2009-01-15
- 发明人: David Middlemiss , Mark Richard Ashton , Edward Andrew boyd , Frederick Arthur Brookfield , Michael George Hunter , Mark Whittaker , Chris Palmer , Eric R. Pettipher
- 申请人: David Middlemiss , Mark Richard Ashton , Edward Andrew boyd , Frederick Arthur Brookfield , Michael George Hunter , Mark Whittaker , Chris Palmer , Eric R. Pettipher
- 申请人地址: GB Abingdon
- 专利权人: Oxagen Limited
- 当前专利权人: Oxagen Limited
- 当前专利权人地址: GB Abingdon
- 优先权: GB0324763.2 20031023
- 主分类号: A61K31/404
- IPC分类号: A61K31/404 ; A61P11/00 ; A61P17/00 ; A61K31/498 ; A61K31/427 ; A61K31/426 ; A61K31/4709 ; A61P29/00
摘要:
The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
公开/授权文献
- US08198314B2 Treatment of CRTH2-mediated diseases and conditions 公开/授权日:2012-06-12